Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(2 sites)
United States
University of Kansas Cancer Center, Westwood, Kansas UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania Last updated January 2026